Date: 2018-08-02
Type of
information: Treatment of the first patient
phase: 2
Announcement: treatment of the first patient
Company: Medivir (Sweden)
Product: remetinostat
Action
mechanism:
- HDAC inhibitor. Remetinostat is a topical, skin-directed inhibitor of histone deacetylases (HDACs). The compound was designed to effectively inhibit HDACs within cutaneous lesions, but to be rapidly broken down in the bloodstream, preventing the side effects associated with systemically administered HDAC inhibitors.
- Medivir has acquired this clinical stage oncology program from TetraLogic Pharmaceuticals in December 2016.
Disease: basal cell carcinoma
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
- The primary objective of the study is to assess the effects of topical remetinostat on the overall response rate in a cohort of BCC patients and could establish that remetinostat has the potential for use in other skin-associated cancers in addition to CTCL. (NCT03180528)
Latest
news:
- • On August 2, 2018, Medivir announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). This clinical study will be conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Medivir will be providing remetinostat drug supply for this study, and will have full access to, and the rights to use, all clinical data after the study is complete.
Is
general: Yes
